...
首页> 外文期刊>Cancer: A Journal of the American Cancer Society >PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
【24h】

PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

机译:非小细胞肺癌中的PD-L1表达:细胞学,小型活组织检查和手术切除标本的比较

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUNDOne immunotherapeutic agent for patients with advanced non-small cell lung carcinoma, pembrolizumab, has a companion immunohistochemistry (IHC)-based assay that predicts response by quantifying programmed death-ligand 1 (PD-L1) expression. The current study assessed the feasibility of quantifying PD-L1 expression using cytologic non-small cell lung carcinoma specimens and compared the results with those from small biopsy and surgical resection specimens.
机译:背景技术免疫治疗剂,用于高级非小细胞肺癌,Pembrolizumab,具有伴随的免疫组织化学(IHC),基于伴随量的测定,其通过定量编程的死亡配体1(PD-L1)表达来预测响应。 目前的研究评估了使用细胞学非小细胞肺癌样本定量PD-L1表达的可行性,并将结果与来自小活组织检查和手术切除术样品的结果进行比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号